GCLC and cancer: The irreversible GCL inhibitor l-buthionine-sulfoximine (BSO) has shown good tolerability in Phase I clinical trials for neuroblastoma when combined with melphalan (NCT00005835, NCT00002730), though its standalone efficacy in inhibiting cancer growth remains limited [[67], [68], [69], [70]].